Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Migoprotafib - Relay Therapeutics

Next Previous
Drug Profile

Migoprotafib - Relay Therapeutics

Alternative Names: GDC 1971; RG 6433; RLY-1971; RO-7517834; SHP2i

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Relay Therapeutics
  • Developer Genentech; Relay Therapeutics
  • Class Amines; Antineoplastics; Benzofurans; Naphthyridines; Piperidines; Pyrazines; Pyrazoles; Pyrazolones; Small molecules; Spiro compounds
  • Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Nov 2025 700365854 CTP Push- KDM, HE
  • 16 Sep 2025 Genentech completes a phase I trial in Colorectal cancer (Combination therapy, Metastatic disease) in USA (PO) (NCT05954871)
  • 16 Sep 2025 Genentech completes a phase I trial in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA (PO) (NCT05954871)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top